EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study

Matteo Sarocchi, Junmin Li iD, Xiao Li iD, Depei Wu, Efreen Montaño Figueroa, Maria Guadalupe Rodriguez, Ming Hou, Carlo Finelli, Hong-Xia Shi, Zhijian Xiao, Esther Natalie Oliva, Liana Gercheva Kyuchukova und 8 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19316 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Matteo Sarocchi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. Hauptthemen laut MEDLINE: Deferasirox, Myelodysplastic Syndromes, Iron Chelating Agents, Iron Overload. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion‐dependent patients with myelodysplastic syndromes (MDS). TELESTO (NCT00940602) was a prospective, placebo‐controlled, randomised study to evaluate the iron chelator deferasirox in patients with low‐ or intermediate‐1–risk MDS and iron overload. Echocardiographic parameters were collected at screening and during treatment. Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. No significant differences between the arms were found in left ventricular ejection fraction, ventricular diameter and mass or pulmonary artery pressure. The absolute number of events was low, but the enrolled patients were younger than average for patients with MDS, with no serious cardiac comorbidities and a modest cardiovascular risk profile. These results support the effectiveness of deferasirox in preventing cardiac damage caused by iron overload in this patient population. Identification of patients developing CHF is challenging due to the lack of distinctive echocardiographic features. The treatment of iron overload may be important to prevent cardiac dysfunction in these patients, even those with moderate CHF risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeferasiroxMyelodysplastic SyndromesIron Chelating AgentsIron OverloadHumansMaleFemaleMiddle AgedAgedProspective StudiesBenzoatesHeart FailureTransfusion ReactionEchocardiographyAdultAged, 80 and overTriazolesBlood Transfusion

Stichwörter der Autor:innen

cardiac dysfunctiondeferasiroxiron chelationiron overloadmyelodysplastic syndromes

Substanzen

DeferasiroxIron Chelating AgentsBenzoatesTriazoles

Autor:innen und Institutionen

  • Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Shanghai Sixth People's Hospital, Shanghai, China.
  • Jiangsu Institute of Hematology, First Affiliated Hospital of Suzhou University, Suzhou, China.
  • Department of Hematology, Hospital General de México Dr Eduardo Liceaga, Mexico City, Mexico.
  • Department of Hematology, Hospital de Especialidades, Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico.

ORCID-Profile: Junmin Li, Xiao Li, Argiris Symeonidis, Emanuele Angelucci

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Sarocchi, M., Li, J., Li, X., Wu, D., Montaño Figueroa, E., Rodriguez, M. G., Hou, M., Finelli, C., Shi, H. X., Xiao, Z., Oliva, E. N., Gercheva Kyuchukova, L., Drummond, M., Symeonidis, A., Velazquez, E. J., Rivoli, G., Izquierdo, M., Kolekar, Y., Spallarossa, P., & Angelucci, E. (2024). Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study. British Journal of Haematology. https://doi.org/10.1111/bjh.19316

Vancouver

Sarocchi M, Li J, Li X, Wu D, Montaño Figueroa E, Rodriguez MG, et al. Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study. British Journal of Haematology. 2024. doi:10.1111/bjh.19316

BibTeX
@article{Sarocchi2024,
  author = {Sarocchi, Matteo and Li, Junmin and Li, Xiao and Wu, Depei and Montaño Figueroa, Efreen and Rodriguez, Maria Guadalupe and Hou, Ming and Finelli, Carlo and Shi, Hong-Xia and Xiao, Zhijian and Oliva, Esther Natalie and Gercheva Kyuchukova, Liana and Drummond, Mark and Symeonidis, Argiris and Velazquez, Eric J and Rivoli, Giulia and Izquierdo, Miguel and Kolekar, Yogita and Spallarossa, Paolo and Angelucci, Emanuele},
  title = {Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19316}
}
Kostenlos starten →